114 related articles for article (PubMed ID: 9377119)
21. Risk of all-cause mortality in HIV infected patients is associated with clinical, immunologic predictors and the CCR5 Δ32 deletion.
Parczewski M; Bander D; Leszczyszyn-Pynka M; Urbanska A; Kaczmarczyk M; Ciechanowicz A; Boron-Kaczmarska A
PLoS One; 2011; 6(7):e22215. PubMed ID: 21789236
[TBL] [Abstract][Full Text] [Related]
22. Distinctive effects of CCR5, CCR2, and SDF1 genetic polymorphisms in AIDS progression.
Hendel H; Hénon N; Lebuanec H; Lachgar A; Poncelet H; Caillat-Zucman S; Winkler CA; Smith MW; Kenefic L; O'Brien S; Lu W; Andrieu JM; Zagury D; Schächter F; Rappaport J; Zagury JF
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(4):381-6. PubMed ID: 9833747
[TBL] [Abstract][Full Text] [Related]
23. CCR5 genotype and plasma beta-chemokine concentration of Brazilian HIV-infected individuals.
Mikawa AY; Tagliavini SA; Costa PI
Braz J Med Biol Res; 2002 Nov; 35(11):1333-7. PubMed ID: 12426633
[TBL] [Abstract][Full Text] [Related]
24. Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment.
Bratt G; Karlsson A; Leandersson AC; Albert J; Wahren B; Sandström E
AIDS; 1998 Nov; 12(16):2193-202. PubMed ID: 9833861
[TBL] [Abstract][Full Text] [Related]
25. Frequency of the HIV-protective CC chemokine receptor 5-Delta32/Delta32 genotype is increased in hepatitis C.
Woitas RP; Ahlenstiel G; Iwan A; Rockstroh JK; Brackmann HH; Kupfer B; Matz B; Offergeld R; Sauerbruch T; Spengler U
Gastroenterology; 2002 Jun; 122(7):1721-8. PubMed ID: 12055576
[TBL] [Abstract][Full Text] [Related]
26. Distribution of the HIV resistance CCR5-Delta32 allele among Egyptians and Syrians.
Salem AH; Batzer MA
Mutat Res; 2007 Mar; 616(1-2):175-80. PubMed ID: 17166523
[TBL] [Abstract][Full Text] [Related]
27. CCR5 Δ32 homozygous cord blood allogeneic transplantation in a patient with HIV: a case report.
Duarte RF; Salgado M; Sánchez-Ortega I; Arnan M; Canals C; Domingo-Domenech E; Fernández-de-Sevilla A; González-Barca E; Morón-López S; Nogues N; Patiño B; Puertas MC; Clotet B; Petz LD; Querol S; Martinez-Picado J
Lancet HIV; 2015 Jun; 2(6):e236-42. PubMed ID: 26423196
[TBL] [Abstract][Full Text] [Related]
28. Co-receptor usage of HIV-1 primary isolates, viral burden, and CCR5 genotype in mother-to-child HIV-1 transmission.
Ometto L; Zanchetta M; Mainardi M; De Salvo GL; Garcia-Rodriguez MC; Gray L; Newell ML; Chieco-Bianchi L; De Rossi A
AIDS; 2000 Aug; 14(12):1721-9. PubMed ID: 10985308
[TBL] [Abstract][Full Text] [Related]
29. Homozygous and heterozygous CCR5-Delta32 genotypes are associated with resistance to HIV infection.
Marmor M; Sheppard HW; Donnell D; Bozeman S; Celum C; Buchbinder S; Koblin B; Seage GR;
J Acquir Immune Defic Syndr; 2001 Aug; 27(5):472-81. PubMed ID: 11511825
[TBL] [Abstract][Full Text] [Related]
30. Infectious cellular load in human immunodeficiency virus type 1 (HIV-1)-infected individuals and susceptibility of peripheral blood mononuclear cells from their exposed partners to non-syncytium-inducing HIV-1 as major determinants for HIV-1 transmission in homosexual couples.
Blaak H; van't Wout AB; Brouwer M; Cornelissen M; Kootstra NA; Albrecht-van Lent N; Keet RP; Goudsmit J; Coutinho RA; Schuitemaker H
J Virol; 1998 Jan; 72(1):218-24. PubMed ID: 9420218
[TBL] [Abstract][Full Text] [Related]
31. Early protective effect of CCR-5 delta 32 heterozygosity on HIV-1 disease progression: relationship with viral load. The SEROCO Study Group.
Meyer L; Magierowska M; Hubert JB; Rouzioux C; Deveau C; Sanson F; Debre P; Delfraissy JF; Theodorou I
AIDS; 1997 Sep; 11(11):F73-8. PubMed ID: 9302436
[TBL] [Abstract][Full Text] [Related]
32. Impact of heterozygosity for the chemokine receptor CCR5 32-bp-deleted allele on plasma virus load and CD4 T lymphocytes in perinatally human immunodeficiency virus-infected children at 8 years of age.
Buseyne F; Janvier G; Teglas JP; Ivanoff S; Burgard M; Bui E; Mayaux MJ; Blanche S; Rouzioux C; Rivière Y
J Infect Dis; 1998 Oct; 178(4):1019-23. PubMed ID: 9806029
[TBL] [Abstract][Full Text] [Related]
33. Cell-associated HIV DNA measured early during infection has prognostic value independent of serum HIV RNA measured concomitantly.
Katzenstein TL; Oliveri RS; Benfield T; Eugen-Olsen J; Nielsen C; Gerstoft J;
Scand J Infect Dis; 2002; 34(7):529-33. PubMed ID: 12195879
[TBL] [Abstract][Full Text] [Related]
34. Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy.
O'Brien TR; McDermott DH; Ioannidis JP; Carrington M; Murphy PM; Havlir DV; Richman DD
AIDS; 2000 May; 14(7):821-6. PubMed ID: 10839590
[TBL] [Abstract][Full Text] [Related]
35. Polymorphism in the CCR5 gene promoter and HIV-1 infection in North Indians.
Kaur G; Singh P; Rapthap CC; Kumar N; Vajpayee M; Sharma SK; Wanchu A; Mehra NK
Hum Immunol; 2007 May; 68(5):454-61. PubMed ID: 17462514
[TBL] [Abstract][Full Text] [Related]
36. Adverse effect of the CCR5 promoter -2459A allele on HIV-1 disease progression.
Knudsen TB; Kristiansen TB; Katzenstein TL; Eugen-Olsen J;
J Med Virol; 2001 Nov; 65(3):441-4. PubMed ID: 11596075
[TBL] [Abstract][Full Text] [Related]
37. Molecular characterization of the CCR 5 gene in seronegative individuals exposed to human immunodeficiency virus (HIV).
Rugeles MT; Solano F; Díaz FJ; Bedoya VI; Patiño PJ
J Clin Virol; 2002 Jan; 23(3):161-9. PubMed ID: 11595595
[TBL] [Abstract][Full Text] [Related]
38. Genetic polymorphism of CCR5 gene and HIV disease: the heterozygous (CCR5/delta ccr5) genotype is neither essential nor sufficient for protection against disease progression. Swiss HIV Cohort.
Morawetz RA; Rizzardi GP; Glauser D; Rutschmann O; Hirschel B; Perrin L; Opravil M; Flepp M; von Overbeck J; Glauser MP; Ghezzi S; Vicenzi E; Poli G; Lazzarin A; Pantaleo G
Eur J Immunol; 1997 Dec; 27(12):3223-7. PubMed ID: 9464809
[TBL] [Abstract][Full Text] [Related]
39. CCR5-Δ32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy.
Henrich TJ; Hanhauser E; Harrison LJ; Palmer CD; Romero-Tejeda M; Jost S; Bosch RJ; Kuritzkes DR
J Infect Dis; 2016 Mar; 213(5):766-70. PubMed ID: 26512140
[TBL] [Abstract][Full Text] [Related]
40. Restriction of HIV type 1 infection in macrophages heterozygous for a deletion in the CC-chemokine receptor 5 gene.
Ometto L; Zanchetta M; Cabrelle A; Esposito G; Mainardi M; Chieco-Bianchi L; De Rossi A
AIDS Res Hum Retroviruses; 1999 Nov; 15(16):1441-52. PubMed ID: 10555107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
